Recent Advances and Perspectives on the Use of Mineralocorticoid Receptor Antagonists for the Treatment of Hypertension and Chronic Kidney Disease: A Review
Chronic kidney disease (CKD) is a major public health concern around the world. It is a significant risk factor for cardiovascular disease (CVD), and, as it progresses, the risk of cardiovascular events increases. Furthermore, end-stage kidney disease severely affects life expectancy and quality of...
Saved in:
| Main Authors: | Kisho Miyasako, Yujiro Maeoka, Takao Masaki |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/13/1/53 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
FIDELIO study: significance and place of finerenone as nonsteroidal mineralocorticoid receptor antagonist in therapy of patients with chronic kidney disease in type 2 diabetes
by: M. S. Shamkhalova, et al.
Published: (2023-12-01) -
Cardiovascular-Kidney-Metabolic Effects: Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists
by: Biykem Bozkurt, et al.
Published: (2025-07-01) -
Aldosterone-Related Cardiovascular Disease and Benefits of Mineralocorticoid Receptor Antagonists in Clinical Practice
by: Maria Alfarano, MD, PhD, et al.
Published: (2025-06-01) -
Obesity, aldosterone excess, and mineralocorticoid receptor activation: Parallel or intersected circumstances?
by: Houry Puzantian, et al.
Published: (2024-12-01) -
Mineralocorticoid receptor overactivation-induced remodeling of obese adipose tissue
by: WEN Runzhi, WANG Li, ZHAO Naiqian
Published: (2025-06-01)